GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Beginning Cash Position

Labiana Health (XMAD:LAB) Beginning Cash Position : €0.00 Mil (As of Dec. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Beginning Cash Position?

Labiana Health's Beginning Cash Position for the quarter that ended in Dec. 2022 was €0.00 Mil.

Labiana Health's annual Beginning Cash Position declined from Dec. 2020 (€2.12 Mil) to Dec. 2021 (€1.55 Mil) but then increased from Dec. 2021 (€1.55 Mil) to Dec. 2022 (€3.28 Mil).


Labiana Health Beginning Cash Position Historical Data

The historical data trend for Labiana Health's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Beginning Cash Position Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22
Beginning Cash Position
2.12 1.55 3.28

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22
Beginning Cash Position - - - -

Labiana Health Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Labiana Health Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Labiana Health's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Labiana Health (XMAD:LAB) Business Description

Traded in Other Exchanges
N/A
Address
Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.